TheraRadar
← Back
Data updated: Jun 28, 2026

OVERSEAS

Generics
NeurologyRespiratory Execution: Excellent

OVERSEAS is a generic drug manufacturer focused on Neurology, Respiratory.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

OVERSEAS at a Glance

  • Strong track record with 83% execution quality across 6 trials
  • Fast trial execution (2 months median completion)

OVERSEAS's Key Drugs

OVERSEAS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

OVERSEAS's Recent FDA Approvals

New NDA/BLA approvals for OVERSEAS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

OVERSEAS's Therapeutic Areas

OVERSEAS's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 67%
1 drugs
Respiratory 33%
0 drugs Phase 1: 3

OVERSEAS's Top Competitors

OVERSEAS's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, LEDERLE, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GE HEALTHCARE specialty
Neurology, Respiratory
LEDERLE big-pharma
Respiratory, Neurology
AZURITY specialty
Neurology, Respiratory
UPJOHN big-pharma
Neurology, Respiratory
ENDO OPERATIONS specialty
Neurology, Respiratory

OVERSEAS Pipeline Snapshot

OVERSEAS has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 3 Phase 1.

0
Phase 3
0
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 2 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges